

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC
ECHO Trial

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Study Design

- **Background:** Randomized, double-blind, phase 3 trial comparing rilpivirine and efavirenz in combination with a fixed background regimen consisting of tenofovir DF-emtricitabine in treatment-naïve adults with HIV
- **Inclusion Criteria (n = 690)**
 - Antiretroviral-naïve adults
 - Age ≥ 18 years
 - HIV RNA $\geq 5,000$ copies/mL
 - No resistance to any study drugs
- **Treatment Arms**
 - Rilpivirine + Tenofovir DF-Emtricitabine
 - Efavirenz + Tenofovir DF-Emtricitabine


Rilpivirine + TDF-FTC QD
(n = 346)

Efavirenz + TDF-FTC QD
(n = 344)

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Results


48 Week Virologic Response (Intention-to-Treat)



Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Results


48 Week Virologic Failure and Discontinuations (Intention-to-Treat)



Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Resistance Results

Incidence of NNRTI Resistance Associated Mutations (RAMs)




The percentages represent the number of participants who developed each specific NNRTI RAM out of the number of participants who developed any NNRTI RAM in that arm of the trial (the n listed at the top of the graph).

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Resistance Results

Incidence of NRTI Resistance Associated Mutations (RAMs)



The percentages represent the number of participants who developed each specific NRTI RAM out of the number of participants who developed any NRTI RAM in that arm of the trial (the n listed at the top of the graph).

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Conclusions

Interpretation: “Rilpivirine showed non-inferior efficacy compared with efavirenz, with a higher virological-failure rate, but a more favourable safety and tolerability profile.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [HRSA.gov](https://www.hrsa.gov). This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

